A PEER-REVIEWED JOURNAL OF RESEARCH AND CLINICAL MEDICINEISSN 1727-2378 (Print)         ISSN 2713-2994 (Online)
Ru
En

Mechanisms of Insulin Resistance Formation in Polycystic Ovarian Disease and Therapeutic Effects from Myo Inositol

DOI:10.31550/1727-2378-2019-166-11-55-60
For citation: Chernukha G.E., Udovichenko M.A., Naydukova A.A. Mechanisms of Insulin Resistance Formation in Polycystic Ovarian Disease and Therapeutic Effects from Myo Inositol. Doctor.Ru. 2019; 11(166): 55–60. DOI: 10.31550/1727-2378-2019-166-11-55-60
01 october 2019

Objective of the Review: to perform a systematic analysis of data from contemporary sources regarding the mechanisms of insulin resistance (IR) formation in polycystic ovarian disease (PCOD) and regarding efficiency of hormone-free therapy for correction of metabolic and reproductive disorders in this group of patients.

Key Points: PCOD is the most common endocrine pathology in women of reproductive age. Patients with PCOD are at high risk of metabolic disorders, such as IR, hyperinsulinemia, disturbed glucose tolerance, type 2 diabetes mellitus, obesity, dislipidemy, hypertension.

Together with hormone-containing drugs in PCOD, drugs increasing sensitivity to insulin, reducing insulin and androgens secretion are used in correction of reproductive disorders. The analysis of literary sources showed that IR in PCOD patients is very often associated with myo inositol (MI) deficiency.

Conclusion: use of MI in PCOD patients improves metabolic and hormone profile, regulates menstrual period, reduces the risk of gestational diabetes mellitus, and improves extracorporal fertilization outcomes. Use of MI is an alternative therapy of metabolic disorders and ovulatory dysfunction in PCOD.

G.E. Chernukha — V.I. Kulakov National Medical Scientific Centre of Obstetrics, Gynaecology and Perinatal Medicine of the Ministry of Health of Russia; 4 Academician Oparin St., Moscow, Russian Federation 117997. eLIBRARY.RU SPIN: 5514-3483. ORCID: http://orcid.org/0000-0002-9065-5689. E-mail: c-galina1@yandex.ru

M.A. Udovichenko — V.I. Kulakov National Medical Scientific Centre of Obstetrics, Gynaecology and Perinatal Medicine of the Ministry of Health of Russia; 4 Academician Oparin St., Moscow, Russian Federation 117997. E-mail: mariia911@yahoo.com

A.A. Naydukova — V.I. Kulakov National Medical Scientific Centre of Obstetrics, Gynaecology and Perinatal Medicine of the Ministry of Health of Russia; 4 Academician Oparin St., Moscow, Russian Federation 117997. E-mail: aleeshka@mail.ru

Contribution: Chernukha G.E. — patient management, study design, eview of critically important material, approval of the final article version; Udovichenko M.A. — a set of clinical material, manuscript text preparation, hematic publications reviewing; Naydukova A.A. — a set of clinical material, data processing analysis and interpretation, hematic publications reviewing.

The authors declare that they do not have any conflict of interests.

Доктор.ру
1 October 15:08
REFERENCES
  1. Homburg R. Polycystic ovary syndrome — from gynecological curiosity to multisystem endocrinopathy. Hum. Reprod. 1996; 11(1): 29–39.
  2. Azziz R. Polycystic ovary syndrome, reproductive endocrinology and infertility. Obstet. Gynecol. 2018; 132(2): 321–36. DOI: 10.1097/AOG.0000000000002698
  3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 2004; 81(1): 19–25.
  4. Rojas J., Chávez M., Olivar L., Rojas M., Morillo J., Mejías J. et al. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the patophysiologic labyrinth. Int. J. Reprod. Med. 2014; 2014: 719050. DOI: 10.1155/2014/719050
  5. De Sousa S.M., Norman R.J. Metabolic syndrome, diet and exercise. Best Pract. Res. Clin. Obstet. Gynaecol. 2016; 37: 140–51. DOI: 10.1016/j.bpobgyn.2016.01.006
  6. Benelli E., Del Ghianda S., Di Cosmo C., Tonacchera M. Combined therapy with myo-inositol and D-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. Int. J. Endocrinol. 2016; 2016: 3204083. DOI: 10.1155/2016/3204083
  7. Tal R., Seifer D.B., Arici A. The emerging role of angiogenic factor dysregulation in the pathogenesis of polycystic ovarian syndrome. Semin. Reprod. Med. 2015; 33(3): 195–207. DOI: 10.1055/s-0035-1552582
  8. Найдукова А.А., Каприна Е.К., Донников А.Е., Чернуха Г.Е. Генетические аспекты формирования синдрома поликистозных яичников. Аку­шерство и гинекология. 2016; 3: 16–22. [Naidukova A.A., Kaprina E.K., Donnikov A.E., Chernukha G.E. Geneticheskie aspekty formirovaniya sindroma polikistoznykh yaichnikov. Akusherstvo i ginekologiya. 2016; 3: 16–22. (in Russian)]. DOI: 10.18565/aig.2016.3.16-22
  9. Ткачук В.А., Воротников А.В. Молекулярные механизмы развития резис­тентности к инсулину. Сахарный диабет. 2014; 2: 29–40. [Tkachuk V.A., Vorotnikov A.V. Molekulyarnye mekhanizmy razvitiya rezistentnosti k insulinu. Sakharnyi diabet. 2014; 2: 29–40. (in Russian)]
  10. Дудинская Е.Н., Браилова Н.В., Стражеско И.Д., Акашева Д.У., Ткачева О.Н., Шестакова М.В. Роль инсулинорезистентности в процессах сосудистого старения. Профилактическая медицина. 2014; 17(2): 35–41. [Dudinskaya E.N., Brailova N.V., Strazhesko I.D., Akasheva D.U., Tkacheva O.N., Shestakova M.V. Rol' insulinorezistentnosti v protsessakh sosudistogo stareniya. Profilakticheskaya meditsina. 2014; 17(2): 35–41. (in Russian)]
  11. Olatunbosun S.T., Griffing G.T. Medscape, endocrynology, insulin resistance, 2017. URL: https://emedicine.medscape.com/article/122501-overview#a4 (дата обращения — 15.04.2019).
  12. Laganà A.S., Vitale S.G., Noventa M., Vitagliano A. Current management of polycystic ovary syndrome: from bench to bedside. Int. J. Endocrinol. 2018; 7234543. DOI: 10.1155/2018/7234543
  13. Das D., Arur S. Conserved insulin signaling in the regulation of oocyte growth, development, and maturation. Mol. Reprod. Dev. 2017; 84(6): 444–59. DOI: 10.1002/mrd.22806
  14. Wu S., Divall S., Nwaopara A., Radovick S., Wondisford F., Ko C. et al. Obesity-induced infertility and hyperandrogenism are corrected by deletion of the insulin receptor in the ovarian theca cell. Diabetes. 2014; 63(4): 1270–82. DOI: 10.2337/db13-1514
  15. Dumesic D.A., Oberfield S.E., Stener-Victorin E., Marshall J.C., Laven J.S., Legro R.S. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr. Rev. 2015; 36(5): 487–525. DOI: 10.1210/er.2015-1018
  16. Zuo T., Zhu M., Xu W. Roles of oxidative stress in polycystic ovary syndrome and cancers. Oxid. Med. Cell Longev. 2016; 2016: 8589318. DOI: 10.1155/2016/8589318
  17. Toprak S., Yönem A., Akir B., Güler S., Azal O., Ozata M. et al. Insulin resistance in nonobese patients with polycystic ovary syndrome. Horm. Res. 2016; 55(2): 65–70. DOI: 10.1159/000049972
  18. Papalou O., Victor V.M., Diamanti-Kandarakis E. Oxidative stress in polycystic ovary syndrome. Curr. Pharm. Des. 2016; 22(18): 2709–22.
  19. Genazzani A.D, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil. Steril. 2004; 81(1): 114–9.
  20. Baillargeon J.P, Iuorno M.J, Nestler J.E. Insulin sensitizers for polycystic ovary syndrome. Clin. Obstet. Gynecol. 2003; 46(2): 325–40.
  21. Чернуха Г.Е., Каприна Е.К., Найдукова А.А. Новые возможности коррекции нарушений репродуктивной системы при синдроме поликистозных яичников. Мед. совет. 2015; 9: 34–8. [Chernukha G.E., Kaprina E.K., Naidukova A.A. Novye vozmozhnosti korrektsii narushenii reproduktivnoi sistemy pri sindrome polikistoznykh yaichnikov. Med. sovet. 2015; 9: 34–8. (in Russian)]. DOI: 10.21518/2079-701X-2015-9-34-38
  22. Ferreira G.D., Germeyer A., de Barros Machado A., do Nascimento T.L., Strowitzki T., Brum I.S. et al. Metformin modulates PI3K and GLUT4 expression and Akt/PKB phosphorylation in human endometrial stromal cells after stimulation with androgen and insulin. Eur. J. Obstet. Gynecol. Reprod. Biol. 2014; 175: 157–62. DOI: 10.1016/j.ejogrb.2014.01.009
  23. Strugaru A.M., Botnariu G., Agoroaei L., Grigoriu I.C., Butnaru E. Metformin induced lactic acidosis — particularities and course. Rev. Med. Chir. Soc. Med. Nat. Iasi. 2013; 117(4): 1035–42.
  24. Agrawal A., Mahey R., Kachhawa G., Khadgawat R., Vanamail P., Kriplani A. Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial. Gynecol. Endocrinol. 2019: 1–4. DOI: 10.1080/09513590.2018.1549656
  25. Genazzani A.D. Inositol as putative integrative treatment for PCOS. Reprod. Biomed. Online. 2016; 33(6): 770–80. DOI: 10.1016/j.rbmo.2016.08.024
  26. Bevilacqua A., Bizzarri M. Inositols in insulin signaling and glucose metabolism. Int. J. Endocrinol. 2018; 2018: 1968450. DOI: 10.1155/2018/1968450
  27. Hurrell R.F. Influence of vegetable protein sources on trace element and mineral bioavailability. J. Nutr. 2003; 133(9): 2973S–7. DOI: 10.1093/jn/133.9.2973S
  28. Sun T.H., Heimark D.B., Nguygen T., Nadler J.L., Larner J. Both myo-inositol to chiro-inositol epimerase activities and chiro- inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem. Biophys. Res. Commun. 2003; 293(3): 1092–8. DOI: 10.1016/S0006-291X(02)00313-3
  29. Milewska E.M., Czyzyk A., Meczekalski B., Genazzani A.D. Inositol and human reproduction: from cellular metabolism to clinical use. Gynecol. Endocrinol. 2016; 32(9): 690–5. DOI: 10.1080/09513590.2016.1188282
  30. Di Paolo G., De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature. 2006; 443(112): 651–7. DOI: 10.1038/nature05185
  31. Paul C., Laganà A.S., Maniglio P., Triolo O., Brady D.M. Inositol’s and other nutraceuticals’ synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives. Gynecol. Endocrinol. 2016; 32(6): 431–8. DOI: 10.3109/09513590.2016.1144741
  32. Unfer V., Nestler J.E., Kamenov Z.A., Prapas N., Facchinetti F. Effects of inositol(s) in women with PCOS: a systematic review of randomized controlled trials. Int. J. Endocrinol. 2016; 2016: 1849162. DOI: 10.1155/2016/1849162
  33. Baillargeon J.P., Iuorno M.J., Apridonidze T., Nestler J.E. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome. Metab. Syndr. Relat. Disord. 2010; 8(2): 127–35. DOI: 10.1089/met.2009.0052
  34. Arya B.K., Haq A.U., Chaudhury K. Oocyte quality reflected by follicular fluid analysis in PCOS: a hypothesis based on intermediates of energy metabolism. Med. Hypoteses. 2012; 78(4): 475–8. DOI: 10.1016/j.mehy.2012.01.009
  35. Laganà A.S., Garzon S., Casarin J., Franchi M., Ghezzi F. Inositol in polycystic ovary syndrome: restoring fertility through a pathophysiology-based approach. Trends Endocrinol. Metab. 2018; 29(11): 768–80. DOI: 10.1016/j.tem.2018.09.001
  36. Nestler J.E., Jakubowicz D.J., de Vargas A.F., Brik C., Quintero N., Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J. Clin. Endocrinol. Metab. 1998; 83(6): 2001–5. DOI: 10.1210/jcem.83.6.4886
  37. Garg D., Tal R. Inositol treatment and art outcomes in women with PCOS. Int. J. Endocrinol. 2016; 2016: 1979654. DOI: 10.1155/2016/1979654
  38. Nestler J.E., Jakubowicz D.J., Reamer P., Gunn R.D., Allan G. Ovulatory and metabolic effects of D-chiroinositol in the polycystic ovary syndrome. N. Engl. J. Med. 1999; 340(17): 1314–20. DOI: 10.1056/NEJM199904293401703
  39. Iuorno M.J., Jakubowicz D.J., Baillargeon J.P., Dillon P., Gunn R.D., Allan G. et al. Effects of D-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr. Pract. 2002; 8(6): 417–23. DOI: 10.4158/EP.8.6.417
  40. Cheang K.I., Baillargeon J.P., Essah P.A., Ostlund R.E., Apridonize T., Islam L. et al. Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. J. Metabolism. 2008; 57(10): 1390–7. DOI: 10.1016/j.metabol.2008.05.008
  41. Isabella R., Raffone E. CONCERN: Does ovary need D-chiroinositol? J. Ovarian Res. 2012; 5(1): 14. DOI: 10.1186/1757-2215-5-14
  42. Harwood K., Vuguin P., Di Martino-Nardi J. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Horm. Res. 2007; 68(5): 209–17. DOI: 10.1159/000101538
  43. Rice S., Christoforidis N., Gadd C., Nikolaou D., Seyani L., Donaldson A. et al. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum. Reprod. 2005; 20(2): 373–81. DOI: 10.1093/humrep/deh609
  44. Heimark D., McAllister J., Larner J. Decreased myo- inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr. J. 2014; 61(2): 111–17.
  45. Chiu T.T.Y., Rogers M.S., Law E.L.K., Briton-Jones C.M., Cheung L.P., Haines C.J. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum. Reprod. (Oxf.). 2002; 17(6): 1591–6.
  46. Chiu T.T.Y., Rogers M.S., Briton-Jones C.M., Haines C.J. Effects of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes. Hum. Reprod. (Oxf.). 2003; 18(2): 408–16.
  47. Papaleo E., Unfer V., Baillargeon J.P., De Santis L., Fusi F., Brigante C. et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol. Endocrinol. 2007; 23(12): 700–3. DOI: 10.1080/09513590701672405
  48. Kamenov Z., Kolarov G., Gateva A., Carlomagno G., Genazzani A.D. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol. Endocrinol. 2015; 31(2): 131–5. DOI: 10.3109/09513590.2014.964640
  49. Unfer V., Carlomagno G., Dante G., Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol. Endocrinol. 2012; 28(7):509–15. DOI: 10.3109/09513590.2011.650660
  50. Regidor P.A., Schindler A.E., Lesoine B., Druckman R. Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Horm. Mol. Biol. Clin. Investig. 2018; 34(2). DOI: 10.1515/hmbci-2017-0067
  51. Fraticelli F., Celentano C., Zecca I.A., Di Vieste G., Pintaudi B., Liberati M. et al. Acta Diabetol. 2018; 55(8): 805–12. DOI: 10.1007/s00592-018-1157-4
  52. Celentano C., Matarrelli B., Pavone G., Vitacolonna E., Mattei P.A., Berghella V. et al. The influence of different inositol stereoisomers supplementation in pregnancy on maternal gestational diabetes mellitus and fetal outcomes in high-risk patients: a randomized controlled trial. J. Matern. Fetal. Neonatal. Med. 2018: 1–9. DOI: 10.1080/14767058.2018.1500545
  53. Genazzani A.D. Inositol as putative integrative treatment for PCOS. Reprod. Biomed. Online. 2016; 33(6): 770–80. DOI: 10.1016/j.rbmo.2016.08.024
  54. Simi G., Genazzani A.R., Obino M.E., Papini F., Pinelli S., Cela V. et al. Inositol and in vitro fertilization with embryo transfer, Int. J. Endocrinol. 2017; 2017: 5469409. DOI: 10.1155/2017/5469409
  55. Mann J.S., Lowther K.M., Mehlmann L.M. Reorganization of the endoplasmic reticulum and development of Ca2+ release mechanisms during meiotic maturation of human oocytes. Biol. Reprod. 2010; 83(4): 578–83. DOI: 10.1095/biolreprod.110.085985
  56. Teede H.J., Misso M.L., Costello M.F., Dokras A., Laven J., Moran L. et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome, Fertil. Steril. 2018; 110(3): 364–79. DOI: 10.1016/j.fertnstert.2018.05.004

Похожие статьи

News

1 October 10:52
A New Issue of Doctor.Ru Internal Medicine, Vol. 21, No. 6 (2022), Published

Find original articles and reviews covering various aspects of сardiology, gastroenterology, internal medicine and the interview with Professor Alexey Nikolaevich Kalyagin

7 July 17:16
A New Issue of Doctor.Ru Neurology Psychiatry, Vol. 21, No. 4 (2022), Published

Find original articles and reviews covering various aspects of neurology, psychiatry and the interview with Professor Alexander Vitalievich Amelin

12 May 11:25
A New Issue of Doctor.Ru Pediatrics, Vol. 21 No. 3 (2022), Published

See the original papers, reviews and clinical cases in headings Pulmonology, Rheumatology, Endocrinology, Neurology, Cross-disciplinary approach and Interview with with an Honoured Scientist of the Sakha (Yakutia) Republic Professor Maria Vasilievna Khandy

4 May 10:02
A New Issue of Doctor.Ru Internal Medicine, Vol. 21, No. 2 (2022), Published

Find original articles and reviews covering various aspects of gastroenterology, internal medicine, rheumatology, endocrinology, special section of postgraduate training and the interview with Professor Dmitry Alexeevich Sychev

18 March 00:00
A New Issue of Doctor.Ru Gynecology, Vol. 21 No. 1 (2022), Published

Find original articles and reviews covering various aspects of obstetrics, perinatology and gynecology, and the interview with Feldberg Dov, MD

All news